Panbio登革熱早期快速檢測(cè)試劑盒

（Panbio Dengue Early）

廣州健侖生物科技有限公司

本公司為大家供應(yīng)各種進(jìn)口品牌登革熱檢測(cè)試劑盒，包括澳洲Panbio、美國(guó)NovaBios、美國(guó)CORTEZ等美國(guó)CDC品牌。主要包括膠體金、酶免、PCR等方法學(xué)。歡迎咨詢(xún)

Panbio登革熱早期快速檢測(cè)試劑盒（Panbio Dengue Early）

非洲工作用登革熱試紙

熱帶國(guó)家旅游用登革熱檢測(cè)試紙

登革熱IgM抗體、登革熱IgG抗體、登革熱NS1抗原、登革熱早期檢測(cè)試劑盒

登革熱核酸檢測(cè)試劑盒

Panbio公司簡(jiǎn)介:
1、1988年成立，2001年在澳大利亞證券交易所上市。
2、Panbio系關(guān)于蟲(chóng)媒感染性疾病及熱帶感染性疾病的專(zhuān)業(yè)供貨商。
3、產(chǎn)品面向蟲(chóng)媒感染性疾病的檢測(cè)，在國(guó)內(nèi)疾控系統(tǒng)具有*的認(rèn)知和認(rèn)可度。
4、2010年銷(xiāo)售800萬(wàn)檢測(cè)試劑，為30多種疾病提供診斷。

Panbio登革熱介紹：

1、登革熱快速檢測(cè)試劑(Dengue Duo Cassette R-DEN03D)
用于定性的快速檢測(cè)人群血清、血漿或全血中登革病毒的IgM及IgG抗體。可在15分鐘內(nèi)檢測(cè)結(jié)果。

2、登革IgM捕捉ELISA(Dengue IgM Capture ELISA E-DEN01M)
用于定性的檢測(cè)人群血清中登革病毒的IgM抗體，用于臨床實(shí)驗(yàn)室對(duì)具有持續(xù)發(fā)燒的登革熱癥狀的病人的輔助診斷。

3、登革IgG捕捉ELISA(Dengo IgG Capture ELISA E-DEN02G)
用于定性檢測(cè)血清中登革病毒(血清型1、2、3及4型)的IgG抗體。用于臨床實(shí)驗(yàn)室對(duì)繼發(fā)登革熱感染的輔助診斷。

4、登革早期ELISA(Dengue Early ELISA E-DEN01P)
用于定性檢測(cè)血清中登革病毒的NS1抗原(血清型1、2、3及4型)。用于臨床實(shí)驗(yàn)室對(duì)有持續(xù)發(fā)燒的登革熱癥狀病人的輔助性診斷。

5、登革IgG間接ELISA(Dengue IgG Indirect ELISA E-DEN01G)
用于定性檢測(cè)血清中登革病毒(血清型1、2、3及4型)的IgG抗體，用于臨床實(shí)驗(yàn)室對(duì)具有持續(xù)發(fā)燒的登革感染癥狀或接觸史的患者的輔助性診斷。

6、登革IgM & IgG聯(lián)檢ELISA(Dengue Duo IgM & IgG Capture ELISA E-DEN01D)
用于定性檢測(cè)血清中登革病毒的IgM和IgG抗體。可以區(qū)分原發(fā)感染與繼發(fā)感染。

Dengue產(chǎn)品介紹

（Panbio Dengue Early）

診斷
臨床醫(yī)生在癥狀發(fā)作前2周內(nèi)應(yīng)考慮登革熱患者。因?yàn)榈歉餆崾菄?guó)家通報(bào)的疾病，所有疑似病例均應(yīng)報(bào)當(dāng)?shù)匦l(wèi)生部門(mén)。可以通過(guò)免疫測(cè)定法，通過(guò)RT-PCR或登革熱非結(jié)構(gòu)蛋白1（NS1）抗原檢測(cè)病毒基因組序列，從疾病早期（發(fā)燒后≤5天）獲得的單個(gè)急性期血清標(biāo)本進(jìn)行實(shí)驗(yàn)室確認(rèn)。病后（發(fā)燒發(fā)生后4天），可用ELISA檢測(cè)登革熱病毒IgM。對(duì)于在發(fā)燒后*周內(nèi)出現(xiàn)的患者，診斷測(cè)試應(yīng)包括登革熱病毒（PCR或NS1）和IgM的檢測(cè)。對(duì)于發(fā)燒發(fā)作后1周的患者，IgM是zui有用的，盡管NS1在發(fā)燒后12天內(nèi)已報(bào)告陽(yáng)性（圖3-01）。在美國(guó)，IgM ELISA和實(shí)時(shí)RT-PCR都被批準(zhǔn)為體外診斷測(cè)試。
在單一診斷標(biāo)本中通過(guò)RT-PCR或NS1抗原存在病毒被認(rèn)為是具有相容臨床和旅行史的患者登革熱的實(shí)驗(yàn)室確認(rèn)。單一血清樣本中的IgM表明zui近可能出現(xiàn)登革熱感染，如果感染zui可能發(fā)生在其他潛在的交叉反應(yīng)性黃病毒（如Zika，西尼羅河，黃熱病和日本腦炎病毒）的地方，則應(yīng)被認(rèn)為是登革熱診斷）不是一個(gè)風(fēng)險(xiǎn)。如果感染可能發(fā)生在其他潛在交叉反應(yīng)性黃病毒循環(huán)的地方，則應(yīng)進(jìn)行分子和血清學(xué)診斷測(cè)試，以檢測(cè)登革熱和其他黃病毒感染的證據(jù)。
在單一血清樣品中通過(guò)ELISA的IgG對(duì)于診斷測(cè)試是不可用的，因?yàn)樗诘歉餆岣腥竞蟊３挚蓹z測(cè)。此外，感染或接種其他黃病毒（如黃熱病或日本腦炎）的人可能會(huì)產(chǎn)生交叉反應(yīng)性黃病毒抗體，產(chǎn)生假陽(yáng)性血清學(xué)登革熱診斷測(cè)試結(jié)果。
登革熱診斷測(cè)試（分子和血清學(xué)）可從幾個(gè)商業(yè)參考診斷實(shí)驗(yàn)室，州公共衛(wèi)生實(shí)驗(yàn)室和CDC獲得。有關(guān)登革熱診斷測(cè)試的咨詢(xún)可以從CDC獲得。
治療
登革熱沒(méi)有特定的抗病藥物。建議患者保持良好的水分，避免阿司匹林（乙酰水楊酸），含阿斯匹林的藥物和其他非甾體抗炎藥（如布洛芬），因?yàn)樗鼈兙哂锌鼓阅堋０l(fā)熱應(yīng)控制對(duì)乙酰氨基酚和溫和的海綿浴。發(fā)燒患者應(yīng)避免蚊蟲(chóng)叮咬，以降低進(jìn)一步傳播的風(fēng)險(xiǎn)。對(duì)于那些發(fā)生嚴(yán)重登革熱的人，可能需要在重癥監(jiān)護(hù)室進(jìn)行密切觀察和頻繁監(jiān)測(cè)。登革熱患者的預(yù)防性血小板輸注不是有益的，可能導(dǎo)致流體過(guò)載。類(lèi)似地，皮質(zhì)類(lèi)固醇的施用沒(méi)有表現(xiàn)出益處并且對(duì)患者有潛在的危害;不應(yīng)使用皮質(zhì)類(lèi)固醇，除了在自身免疫相關(guān)并發(fā)癥（如嗜血細(xì)胞淋巴組織細(xì)胞增多癥或免疫性血小板減少性紫癜）的情況下。

預(yù)防
在美國(guó)沒(méi)有疫苗可用，盡管1已被許可在墨西哥，菲律賓，巴西和泰國(guó)使用。無(wú)預(yù)防可預(yù)防登革熱。旅行期間的旅行時(shí)間和疾病發(fā)生率（如雨季和流行期間）風(fēng)險(xiǎn)增加。經(jīng)常到熱帶旅游的旅客若采取以下預(yù)防措施，應(yīng)避免蚊蟲(chóng)叮咬
選擇具有良好屏幕的門(mén)窗或空調(diào)的住宿，如果可能的話(huà)。蚊子蚊子通常住在室內(nèi)，經(jīng)常在黑暗，陰涼的地方，如壁櫥，床下，窗簾，浴室和門(mén)廊上。建議游客在這些地區(qū)使用殺蟲(chóng)劑去除蚊子。

（Panbio Dengue Early）

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的Panbio產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱(chēng)】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

references：

DIAGNOSIS
Clinicians should consider dengue in a patient who was in an endemic area within 2 weeks before symptom onset. Because dengue is a nationally notifiable disease, all suspected cases should be reported to the local health department. Laboratory confirmation can be made from a single acute-phase serum specimen obtained early (≤5 days after fever onset) in the illness by detecting viral genomic sequences with RT-PCR or dengue nonstructural protein 1 (NS1) antigen by immunoassay. Later in the illness (≥4 days after fever onset), IgM against dengue virus can be detected with ELISA. For patients presenting during the first week after fever onset, diagnostic testing should include a test for dengue virus (PCR or NS1) and IgM. For patients presenting >1 week after fever onset, IgM is most useful, although NS1 has been reported positive up to 12 days after fever onset (Figure 3-01). In the United States, both IgM ELISA and real-time RT-PCR are approved as in vitro diagnostic tests.
Presence of virus by RT-PCR or NS1 antigen in a single diagnostic specimen is considered laboratory confirmation of dengue in patients with a compatible clinical and travel history. IgM in a single serum sample suggests a probable recent dengue infection and should be considered diagnostic for dengue if the infection most likely occurred in a place where other potentially cross-reactive flaviviruses (such as Zika, West Nile, yellow fever, and Japanese encephalitis viruses) are not a risk. If infection is likely to have occurred in a place where other potentially cross-reactive flaviviruses circulate, both molecular and serologic diagnostic testing should be performed to detect evidence of infection with dengue and the other flaviviruses.
IgG by ELISA in a single serum sample is not useful for diagnostic testing because it remains detectable for life after a dengue infection. In addition, people infected with or vaccinated against other flaviviruses (such as yellow fever or Japanese encephalitis) may produce cross-reactive flavivirus antibodies, yielding false-positive serologic dengue diagnostic test results.
Dengue diagnostic testing (molecular and serologic) is available from several commercial reference diagnostic laboratories, state public health laboratories, and CDC . Consultation on dengue diagnostic testing can be obtained from CDC.
TREATMENT
No specific antiviral agents exist for dengue. Patients should be advised to stay well hydrated and to avoid aspirin (acetylsalicylic acid), aspirin-containing drugs, and other nonsteroidal anti-inflammatory drugs (such as ibuprofen) because of their anticoagulant properties. Fever should be controlled with acetaminophen and tepid sponge baths. Febrile patients should avoid mosquito bites to reduce risk of further transmission. For those who develop severe dengue, close observation and frequent monitoring in an intensive care unit setting may be required. Prophylactic plaet transfusions in dengue patients are not beneficial and may contribute to fluid overload. Similarly, administration of corticosteroids has no demonstrated benefit and is potentially harmful to patients; corticosteroids should not be used except in the case of autoimmune-related complication (such as hemophagocytic lymphohistiocytosis or immune thrombocytopenia purpura).
PREVENTION
No vaccine is available in the United States, although 1 has been licensed for use in Mexico, the Philippines, Brazil, and Thailand. No prophylaxis is available to prevent dengue. Risk increases with duration of travel and disease incidence in the travel destination (such as during the rainy season and during epidemics). Travelers going to the tropics for any length of time should avoid mosquito bites by taking the following preventive measures